Best-in-Class Experimental Gut Bacteria-Based Medicine: MRM Health Lands US$64 Series B (GeneOnline)

Belgium-based MRM Health secured €55M ($64M) in Series B financing, led by Biocodex, to fund a Phase 2b trial of MH002, its six-strain microbial consortium for ulcerative colitis, and to expand its microbiome pipeline. Early Phase 2a trials in ulcerative colitis and pouchitis showed MH002 was safe and hinted at meaningful efficacy, with remission rates up to 46%. Built on the CORAL® platform, MH002 benefits from a unique single-substance manufacturing process, ensuring consistent dosing and regulatory scalability. The financing also includes a strategic collaboration with Biocodex to bolster development and production of live biotherapeutics.